New Developments in Therapeutic Chelating Agents as Antidotes for Metal Poisoning

References

• Aymon P. Risk of leukemia near nuclear plant. Cancer J. 1990; 3: 61
   Google Scholar
• Metal-Binding in Medicine, M. J. Seven, L. A. Johnson. Lippincott, Philadelphia 1960
   Google Scholar
• Seven M. J., Johnson L. A. Biol, aspects of metal binding. Fed. Proc 1961; 20(Suppl. 10)1
   Google Scholar
• Catsch A. Dekorporierung Radioaktiver and Stabiler Metallionen, Therapeutische Grundlage. K. Theimig, Munich 1968
   Google Scholar
• Jones M. M., Pratt T. H. Therapeutic chelating agents. J. Chem. Ed. 1976; 53: 342
   PubMed Web of Science ®Google Scholar
• Catsch A., Harmuth-Hoene A.-E., Mellor D. P. The Chelation of Heavy Metals. Pergamon Press, Oxford 1979
   Google Scholar
• Bulman R. A., May P. J. The present status of chelating agents in medicine. Prog. Med. Chem. 1983; 20: 225
   PubMedGoogle Scholar
• Bulman R. A. The chemistry of chelating agents in medical sciences. Structure Bonding 1987; 67: 91
   Google Scholar
• Williams D. R., Halstend B. W. Chelating agents in medicine. J. Toxicol: Clin. Toxicol 1982–1983; 19: 1081
   PubMed Web of Science ®Google Scholar
• Schubert J. Approaches to treatment of poisoning by both radioactive and nonradioactive elements encountered in atomic energy operations. Proc. Int. Conf. Peaceful Uses of Atomic Energy, Geneva, 1955; Vol. 13: 274
   Google Scholar
• Aaseth J. Recent advances in the therapy of metal poisonings with chelating agents. Human. Toxicol 1983; 2: 257
   PubMedGoogle Scholar
• Schubert J. S. Removal of radioelements from the mammalian body. Ann. Rev. Nucl. Sci. 1955; 5: 369
   PubMedGoogle Scholar
• Jones M. M. Therapeutic chelating agents. Metal Ions in Biological Systems, H. Sigel. Marcel Dekker, New York 1983; Vol. 16: 47
   Google Scholar
• Chenoweth M. B. Chelation as a mechanism of pharmacological action. Pharmacol. Rev. 1956; 8: 57
   PubMed Web of Science ®Google Scholar
• Chenoweth M. B. Clinical uses of metal-binding drugs. Clin. Pharmacol Ther. 1963; 9: 365
   Google Scholar
• Pullman T. N., Lavender A. R., Forland M. Synthetic chelating agents in clinical medicine. Annu. Rev. Med. 1963; 14: 175
   PubMed Web of Science ®Google Scholar
• Jones M. M. Heavy-metal detoxification using sulfur compounds. Sulfur Rep. 1985; 4: 119
   Google Scholar
• Cantilena L. R., Jr., Klaassen C. D. Comparison of the effectiveness of several chelators after single administration on the toxicity, excretion and distribution of cadmium. Toxicol. Appl. Pharmacol 1981; 58: 452
   PubMed Web of Science ®Google Scholar
• Günter R. Der Einfluss von Chelatbildem auf die Verteilung und Ausscheidung von Radioeisen bei der Ratte. Naunyn Schmeideberg's Arch. Exp. Pathol. Pharmakol 1969; 262: 405
   PubMedGoogle Scholar
• Catsch A. Experimenteller Beitrag zur Frage der Bleidekorporation durch Chelatbildner. Arzneim. Forsch. 1967; 17: 493
   PubMedGoogle Scholar
• Zvirblis P., Ellin R. I. Acute systematic toxicity of pure dimercaprol and trismercaptopropane. Toxicol. Appl. Pharmacol 1976; 36: 397
   Web of Science ®Google Scholar
• Stine E. R., Hsu C.-H., Hoover T. D., Aposhian H. V., Cater D. E. N-(2,3-dimercaptopropyl)phthalamidic acid: protectionin vivo andin vitro, against arsenic intoxication. Toxicol. Appl. Pharmacol 1984; 75: 329
   PubMed Web of Science ®Google Scholar
• Aposhian H. V., Carter D. E., Hoover T. D., Hsu C.-H., Maiorino R. M., Stine E. DMSA, DMPS, and DMPA — as arsenic antidotes. Fundam. Appl. Toxicol 1984; 4: S58
   Google Scholar
• Aposhian H. V. Penicillamine and analogous chelating agents. Ann. N.Y. Acad. Set 1971; 179: 481
   PubMed Web of Science ®Google Scholar
• Aaseth J., Alexander J., Raknerud N. Treatment of mercuric chloride poisoning with dimercaptosuccinic acid and other complexing thiols. Acta Pharmacol. Toxicol. 1982; 42: 248
   Google Scholar
• Aposhian H. P., Tadlock C. H., Moon T. E. Protection of mice against the lethal effects of sodium arsenite — a quantitative comparison of a number of chelating agents, Toxicol. Appl. Pharmacol 1981; 61: 385
   PubMed Web of Science ®Google Scholar
• Stohler H. R., Frey J. R. Chemotherapy of experimental schistosomiasis mansoni: influence of dimercaptosuccinic acid on the toxicity and antischistosomal activity of sodium antimony dimercaptosuccinate and other antimony compounds in mice. Ann. Trop Med. Parasitol 1964; 58: 431
   PubMed Web of Science ®Google Scholar
• Planas-Bohne F., Gabard B., Schäffer E. H. Toxicological studies on sodium 2,3-dimercaptopropane-1-sulfonate in the rat. Azneim. Forsch. 1980; 30: 1291
   PubMed Web of Science ®Google Scholar
• Pfister G., Catsch A., Nigrovic V. Antidote bei der akuten Eisenvergiftung. Arzneim. Forsch. 1967; 17: 748
   PubMedGoogle Scholar
• Smyth H. F., Jr., Carpenter C. P., Weil C. S. Range-finding toxicity data. List III. J. Ind. Hyg. Toxicol. 1949; 31: 60
   PubMedGoogle Scholar
• Stavreva M. Toxicity and mechanism of action of triethylenetertramine (TETA) used as a siccative for anticorrosive epoxide protective coatings (in Bulgarian). Khig. Zdraveopaz 1979; 22(2)179, Chem. Abstr., 91, 1522216s
   Google Scholar
• Johary N. S., Owen L. N. Dithiols. XVIII. Some water soluble derivatives containing the sulfonic acid group. J. Chem. Soc. 1955; 1307
   Google Scholar
• Owen L. N., Sultanbawa M. U. S. Olefinic acids. VII. The addition of thiols to propiolic and acetylene dicarboxylic acid. J. Chem. Soc 1949; 3109
   Google Scholar
• Walshe J. M. Penicillamine, a new oral therapy for Wilson's disease. Am. J. Med. 1956; 21: 487
   PubMed Web of Science ®Google Scholar
• Walshe J. M. Copper in patients with Wilson's disease. Q. J. Med. 1973; 42(no. 167)441
   PubMedGoogle Scholar
• Gibbs K., Walshe J. M. The effect of certain chelating compounds on the urinary excretion of copper by the rat: observations on their clinical significance. Clin. Sci. Mol. Med. 1977; 53: 317
   PubMedGoogle Scholar
• Walshe J. M. Wilson's disease (hepatolenticular degeneration). Handbook of Clinical Neurology, P. J. Vinken, G. W. Bruyn. North Holland, Amsterdam 1976; Vol. 27: 379
   Google Scholar
• Walshe J. M. Toxic reactions to penicillamine in patients with Wilson's disease. Postgrad. Med. J. 1968; 6, (Suppl. “Penicillamine”)
   Google Scholar
• Walshe J. M. Wilson's disease: yesterday, today and tomorrow. Movement Disorders 1988; 3: 10
   PubMed Web of Science ®Google Scholar
• Volf V. Treatment of Incorporated Transuranium Elements. Tech. Rep. Ser. No. 184, International Atomic Energy Agency, Vienna 1978
   Google Scholar
• Sunderman F. W., Sr. Use of sodium diethyldithiocarbamate in the treatment of nickel carbonyl poisoning. Ann. Clin. Lab. Sci. 1990; 20: 12
   PubMed Web of Science ®Google Scholar
• Borthwick T. R., Benson G. D., Schugar H. J. 2,3,2-Tetramme — a potent cupriuretic agent. Proc. Soc. Exp. Biol. Med. 1979; 162: 227
   PubMed Web of Science ®Google Scholar
• Borthwick T. R., Benson G. D., Schugar H. J. Copper chelating agents, a comparison of cupriuretic responses to various tetramines and d-penicillamine. J. Lab. Clin. Med. 1980; 95: 575
   PubMed Web of Science ®Google Scholar
• Jones M. M. An alternative model for the selection of therapeutic chelating agents. Inorg. Chim. Act 1985; 107: 235
   Web of Science ®Google Scholar
• Jones M. M., May P. M. The effect of kinetic factors on the thermodynamic evaluations of therapeutic chelating agents. Inorg. Chim. Acta 1987; 138: 67
   Web of Science ®Google Scholar
• Jones M. M., Wilson D. J., Topping R. J., Laurie S. H. The role of rate determining steps in the decorporation of toxic metal ions. Inorg. Chim. Acta 1988; 152: 159
   Web of Science ®Google Scholar
• Weitl F. L., Harris W. H., Raymond K. N. Sulfonated catecholamide analogs of enterobactin as iron sequestering agents. J. Med. Chem. 1979; 22: 1281
   PubMed Web of Science ®Google Scholar
• Hallman P. S., Perrin D. D., Watt A. E. The computed distribution of copper(II) and zinc(II) among seventeen amino acids present in human blood plasma. Biochem. J. 1971; 121: 549
   PubMed Web of Science ®Google Scholar
• Agarwal R. R., Perrin D. D. Computer-based approach to chelation therapy: theoretical study of some chelating agents for the selective removal of toxic metals from plasma. Agents Actions 1976; 15: 667
   Google Scholar
• Corrie A. M., Touch M. L. D., Williams D. R. Thermodynamic considerations in co-ordination. XIV. Formation constants for lead(II)-amino-acid complexes and their use in computing the complexing competition between lead(II) andin vivo essential metal ions, and in computer evaluation of ligands currently employed as lead(II) chelating therapeuticals. J. Chem. Soc., Dalton Trans. 1973; 2563
   Google Scholar
• May P. M., Williams D. R. Computer simulation of chelation therapy. FEBS Lett. 1977; 78: 134
   PubMed Web of Science ®Google Scholar
• Duffield J. R., Williams D. R. The environmental chemistry of radioactive waste disposal. Chem. Soc. Rev. 1986; 15: 291
   Web of Science ®Google Scholar
• Duffield J. R., May P. M., Williams D. R. Computer simulation of metal ion equilibria in biofluids. IV. Plutonium speciation in human blood plasma and chelation therapy using polyaminocarbox-ylic acids. J. Inorg. Biochem. 1984; 20: 199
   PubMed Web of Science ®Google Scholar
• Jones D., Smith G. L., May P. M., Williams D. R. Assessment of pharmaceutical agents for removing cadmium from humans using chemical speciation models. Inorg. Chim. Acta 1984; 93: 93
   Web of Science ®Google Scholar
• Martell A. E. The design and synthesis of chelating agents. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier/North Holland, New York 1981; 67
   Google Scholar
• Hancock R. D., Martell A. E. The chelate, cryptate and macrocycle effects. Comments Inorg. Chem. 1989; 6: 237
   Google Scholar
• Hancock R. D., Evers A., Ngwenya M. P., Wade P. W. Structurally reinforced macrocyclic ligands that show greatly enhanced selectivity for metal ions on the basis of the matching in size between metal ion and the macrocyclic cavity. J. Chem. Soc., Chem. Commun. 1987; 1129
   Google Scholar
• Hancock R. D., Martell A. E. Ligand design for selective complexation of metal ions in aqueous solution. Chem. Rev. 1989; 89: 1875
   Web of Science ®Google Scholar
• Garrett T. M., Miller P. W., Raymond K. N. 2,3-Dihy-droxyterephthalamides: highly efficient iron(III)-chelating agents. Inorg. Chem. 1989; 28: 128
   Web of Science ®Google Scholar
• Gyparaki M., Porter J. B., Hirani S., Streater M., Hider R. C., Huehns E. R. In vivo evaluation of hydroxypyridinone iron chelators in a mouse model. Acta Haematol. 1987; 78: 217
   PubMed Web of Science ®Google Scholar
• Huehns E. R., Porter J. B., Hider R. C. Selection of hydroxypyrid-4-ones for the treatment of iron overload usingin vitro andin vivo models. Hemoglobin 1989; 12: 593
   Google Scholar
• Pitt C. G. Structure and activity relationship relationships of iron chelating drugs. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier/North Holland, New York 1981; 105
   Google Scholar
• Raymond K. N., Pecoraro V. L., Weitl F. L. Design of new chelating agents. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier/North Holland, New York 1981; 165
   Google Scholar
• Hancock R. D., Shaikjee M. S., Dobson S. M., Boeyens J. C. A. The stereochemical activity or non-activity of the “inert” pair of electrons on lead(II) in relation to its complex stability and structural properties. Some considerations in ligand design. Inorg. Chim. Acta 1988; 154: 229
   Web of Science ®Google Scholar
• Raymond K. N., Smith W. L. Actinide specific chelating agents. Structure Bonding 1981; 43: 159
   Web of Science ®Google Scholar
• Harris W. R. Structure-reactivity relation for the complexation of Ni, Cd, Zn, and Fe. J. Coord. Chem. 1983; 13: 17
   Web of Science ®Google Scholar
• Singh P. K., Jones M. M., Jones S. G., Gale G. R., Atkins L. M., Smith A. B., Bulman R. A. Effect of chelating agent structure on the mobilization of cadmium from intracellular deposits. J. Toxicol. Environ. Health 1989; 28: 501
   PubMed Web of Science ®Google Scholar
• Eybl V., Sykora J., Koutensky J., Mertl F., Jones M. M. Interaction of some chelating agents with cadmiumin vivo and the molecular connectivity. QSAR in Toxicology and Xenobiotics, M. Tichy. Elsevier, Amsterdam 1985; 179
   Google Scholar
• Jones M. M., Singh P. K., Jones S. G., Mukundan C., Banton J. A., Gale G. R., Smith A. B., Atkins L. M. Chirality, charge and chain branching effects on dithiocarbamate-induced mobilization of cadmium from intracellular deposits in mice, Submitted
   Google Scholar
• Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes 1989; 38: 1207
   PubMed Web of Science ®Google Scholar
• Koren G., Bentur Y., Strong D., Harvey E., Klein J., Baumal R., Spielberg S. P., Freedman M. H. Acute changes in renal function associated with deferoxamine therapy. Am. J. Dis. Child. 1989; 143: 1077
   PubMedGoogle Scholar
• Herschko C. Oral iron chelating drugs: coming but not yet ready for clinical use. Br. J. Med. 1988; 296: 1081
   PubMedGoogle Scholar
• Microbial Iron Metabolism, J. B. Nielands. Academic Press, New York 1974
   Google Scholar
• Raymond K. N., Cass M. E., Evans S. L. Metal sequestering agents in bioinorganic chemistry: enterobactin mediated iron transport inE. coli and biomimetic applications. Pure Appl. Chem. 1989; 59: 771
   Web of Science ®Google Scholar
• Raymond K. N., Miller G., Matzanke B. Complexation of iron by siderophores: a review of their solution and structural chemistry and biological function. Top. Curr. Chem. 1984; 123: 49
   Web of Science ®Google Scholar
• Porter J. B., Huehns E. R., Hider R. C. The development of iron chelating drugs. Balliere's Clin. Haematol. 1989; 2(2)257
   PubMedGoogle Scholar
• Grady R. W., Peterson C. M., Jones R. L., Graziano J. H., Bargava K. K., Berdoukas V. A., Kokkini G., Loukopolous D., Cerami A. Rhodotorulic acid-investigation of its potential as an iron chelating drug. J. Pharmacol. Exp. Ther. 1979; 209: 342
   PubMed Web of Science ®Google Scholar
• Miller M. J. Synthesis and therapeutic potential of hydroxamic based siderophores and analogs. Chem. Rev. 1989; 89: 1563
   Web of Science ®Google Scholar
• Monzyk B., Crumbliss A. L. Mechanism of ligand substitution on high-spin iron(III) by hydroxamic acid chelators. Thermodynamic and kinetic studies on the formation and dissociation of a series of monohydroxamatoiron(III) complexes. J. Am. Chem. Soc 1979; 101: 6203
   Web of Science ®Google Scholar
• Brink C. P., Crumbliss A. L. Kinetics, mechanism and thermodynamics of aqueous iron(III) chelation and dissociation: influence of carbon and nitrogen substituents in hydroxamic acid ligands. Inorg. Chem. 1984; 23: 4708
   Web of Science ®Google Scholar
• Fish L. L., Crumbliss A. L. Comparison of the kinetics, mechanism and thermodynamics of aqueous iron(III) chelation and dissociation by hydroxamic oxo and thio acid ligands. Inorg. Chem. 1985; 24: 2198
   Web of Science ®Google Scholar
• Rodgers S. J., Raymond K. N. Ferric ion sequestering agents. XI. Synthesis and kinetics of iron removal from transferrin of catechoyl derivatives of desferrioxamine B. J. Med. Chem. 1983; 26: 439
   PubMed Web of Science ®Google Scholar
• Raymond K. N., Pecoraro V. L., Welti F. L. Design of new chelating agents. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier/North Holland, New York 1981
   Google Scholar
• Turowski P. N., Rodgers S. J., Scarrow R. C., Raymond K. N. Ferric ion sequestering agents. XVIII. Two dihydroxamic acid derivatives of EDTA and DTPA. Inorg. Chem. 1988; 27: 474
   Web of Science ®Google Scholar
• Graziano J. H., Grady R. W., Cerami A. The identification of 2,3-dihydroxy-benzoic acid as a potentially useful iron-chelating drug. J. Pharmacol. Exp. Ther. 1974; 196: 478
   Google Scholar
• Peterson C. M., Graziano J. H., Grady R. W., Jones R. L., Vlassara H. V., Canale V. C., Miller D. R., Cerami A. M. Chelation studies with 2,3-dihydroxybenzoic acid in patients with β-thalassemia major. Br. J. Haematol. 1976; 33: 477
   PubMed Web of Science ®Google Scholar
• Harris W. R., Raymond K. N., Weitl F. L. Ferric ion sequestering agents. VI. The spectrophotometric and potentiometric evaluation of sulfonated triscatecholate ligands. J. Am. Chem. Soc 1981; 103: 1667
   Web of Science ®Google Scholar
• Raymond K. N., Cass M. A., Evans S. L. Metal sequestration agents in bioinorganic chemistry; enterobactin mediated iron transport inE. coli and biomimetic applications. Pure Appl. Chem. 1987; 59: 771
   Web of Science ®Google Scholar
• Pecoraro V. L., Weitl F. L., Raymond K. N. Ferric ionspecific sequestering agents. VII. Synthesis, iron-exchange kinetics, and stability constants of N-substituted sulfonated catechoylamide analogues of enterobactin. J. Am. Chem. Soc. 1981; 103: 5133
   Web of Science ®Google Scholar
• Rodgers S. J., Lee C.-W., Ng C. Y., Raymond K. N. Ferric ion sequestering agents. XV. Synthesis, solution chemistry and electrochemistry of a new cationic analog of enterobactin. Inorg. Chem. 1987; 26: 1622
   Web of Science ®Google Scholar
• Cikrt M., Ponka P., Necas E., Neuwirt J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br. J. Haematol. 1980; 45: 275
   PubMed Web of Science ®Google Scholar
• Ponka P., Wilczynska A. Iron chelating potential of pyridoxal isonicotinoyl hydrazone and structurally related compounds. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier/North Holland, New York 1981; 287
   Google Scholar
• Ponka P., Grady R. W., Wilczynska A., Schulman H. H. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone. Bichim. Biophys. Acta 1984; 802: 477
   PubMed Web of Science ®Google Scholar
• Hoy T., Humphrys J., Jacobs A., Williams A., Ponka P. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br. J. Haematol. 1979; 43: 443
   PubMed Web of Science ®Google Scholar
• Ponka P., Richardson D., Baker E., Schulman H. M., Edward J. T. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and he-patocytes. Biochim. Biophys. Acta 1988; 967: 122
   PubMed Web of Science ®Google Scholar
• Herschko C., Avramovici-Grisaru S., Link G., Gelfand L., Sorel S. Mechanism ofin vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J. Lab. Clin. Med. 1981; 98: 99
   PubMed Web of Science ®Google Scholar
• Avramovici-Grisaru S., Sorel S., Link G., Herschko C. Synthesis of pyridoxal isonicotinoyl hydrazones and thein vivo ironremoval properties of some pyrodixal derivatives. J. Med. Chem. 1983; 26: 298
   PubMed Web of Science ®Google Scholar
• Herschko C., Weatherall D. J. Iron-chelating therapy. Crit. Rev. Clin. Lab. Sci. 1988; 26: 303
   PubMed Web of Science ®Google Scholar
• Johnson D. K., Pippard M. J., Murphy T. B., Rose N. J. Anin vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs. J. Pharmacol. Exp. Ther. 1982; 221: 399
   PubMed Web of Science ®Google Scholar
• Brittenham G. M. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin. Hematol 1990; 27: 112
   PubMed Web of Science ®Google Scholar
• Frost A. E., Freedman H. H., Westerback S. J., Martell A. E. Chelating tendencies ofN,N′-ethylenebis-[2-(o-hydroxyphenyl)]-glycine. J. Am. Chem. Soc. 1958; 80: 530
   Web of Science ®Google Scholar
• L'Eplattenier F., Murase I., Martell A. E. New multidentate ligands. VI. Chelating tendencies ofN,N′-di(2-hydroxybenzyl-ethylenediamine-N,N′-diacetic acid. J. Am. Chem. Soc. 1967; 89: 837
   Web of Science ®Google Scholar
• Grady R. W., Jacobs A. The screening of potential iron chelating drugs. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier/North Holland, New York 1981; 133
   Google Scholar
• Hider R. C., Kontoghiorghes G. J., Silver J. Pharmaceutical Compositions, U.K. Patent. GB 2 118 176, 1983, 2 136 807, 1984; 2 146 990, 1984
   Google Scholar
• Kontoghiorghes G. J. New orally active iron chelators. Lancet 1985; 1: 817
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes G. J., Hoffbrand A. V. Orally active α-ketohydroxy pyridine iron chelators intended for clinical use:in vivo studies in rabbits. Br. J. Haematol 1986; 62: 607
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes G. J. Orally active α-ketohydroxypyridine iron chelators: studies in mice. Mol. Pharmacol 1986; 30: 670
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes G. J., Sheppard L., Chambers S. New synthetic approach and iron chelating studies on 1-alkyl-2-methyl-3-hydroxypyrid-4-ones. Arzneim. Forsch./Drug Res. 1987; 37: 1099
   PubMed Web of Science ®Google Scholar
• Brock J. H., Licéaga J., Arthur H. M. L., Kontoghiorghes G. J. Effect of novel 1-alkyl-3-hydroxy-2-methyipyrid-4-one chelators on uptake and release of iron from macrophages. Am. J. Hematol. 1990; 34: 21
   PubMed Web of Science ®Google Scholar
• Porter J. B., Hoyes K. P., Abeysinghe R., Huehns E. R., Hider R. C. Animal toxicology of iron chelator LI. Lancet 1989; 2: 156
   PubMed Web of Science ®Google Scholar
• Porter J. B., Gyparaki M., Burke L. C., Huehns E. C., Sarpong P., Saez V., Hider R. C. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and iron binding constant. Blood 1988; 72: 1497
   PubMed Web of Science ®Google Scholar
• Pitt C. G., Gupta G., Estes W. E. The selection and evaluation of new chelating agents for the treatment of iron overload. J. Pharmacol. Exp. Ther. 1979; 208: 1978
   Web of Science ®Google Scholar
• Pitt C. G., Bao Y., Thompson J., Wani M. C., Rosenkrantz H., Metterville J. Esters and lactones of phenolic aminocar-boxylic acids: prodrugs for iron chelation. J. Med. Chem. 1986; 29: 1231
   PubMed Web of Science ®Google Scholar
• Scarrow R. C., Raymond K. N. Synthesis ofN-alkyl-3-hydroxy-2(lH)-pyridinones and coordination complexes with iron(III). Inorg. Chem. 1988; 27: 4140
   Google Scholar
• Cohen A. R., Mizanin J., Schwartz E. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J. Pediatr. 1989; 115: 151
   PubMed Web of Science ®Google Scholar
• Mahoney J. R., Jr., Hallaway P. E., Hedlund B. E., Eaton J. W. Acute iron poisoning: rescue with macromolecular chelators. J. Clin. Invest. 1989; 84: 1362
   PubMed Web of Science ®Google Scholar
• Thalassemia: Pathophysiology and Management, Parts A and B, Birth Defects: Original Article Series, S. Fucharoen, P. T. Rawley, N. W. Paul. Alan R. Liss, New York 1988; Vol. 23, No. 5A
   Google Scholar
• Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches, C. D. Buckner, R. P. Gale, G. Lucarelli. Prog, in Clin. Biol. Res. Ser., Alan R. Liss, New York 1989; Vol. 309
   Google Scholar
• Durbin P. W. Plutonium in mammals: influence of pfutonium chemistry, route of administration, and physiological status of the animal on initial distribution and long-term metabolism. Health Phys. 1975; 29: 495
   PubMed Web of Science ®Google Scholar
• Duffield J. R., Taylor D. M. The biochemistry of the actinides. Handbook on the Physics and Chemistry of the Actinides, A. J. Freeman, C. Keller. Elsevier/North Holland, Amsterdam 1986; Vol. 4: 129
   Google Scholar
• Schubert J., Fried J., Rosenthal M. W., Lindenbaum A. Tissue distribution of monomeric and polymeric plutonium as modified by a chelating agent. Rad. Res. 1961; 15: 220
   PubMed Web of Science ®Google Scholar
• Lushbaugh C. C., Washburn L. C. FDA IND approval for ZnDTPA, new clinical agent for decorporation therapy of actinides. Health Phys. 1979; 36: 472
   PubMed Web of Science ®Google Scholar
• Durbin P. W., Jueng N., Jones E. S., Weitl F. L., Raymond K. N. Specific sequestering agents for the actinides. X. Enhancement of238Pu elimination from mice by poly(catechoylamide) ligands. Rad. Res. 1984; 99: 85
   PubMed Web of Science ®Google Scholar
• Taylor D. M. Acceleration of the natural rate of elimination of transuranium elements from the mammalian body. Handbook on the Physics and Chemistry of the Actinides, A. J. Freeman, C. Keller. Elsevier/North Holland. 1990; Vol. 5
   Google Scholar
• Durbin P. W., Jones E. S., Raymond K. N., Weitl F. L. Specific sequestering agents for the actinides. IV. Removal of238Pu(IV) from mice by sulfonated tetrameric catechoyl amides. Rad. Res. 1980; 81: 170
   PubMed Web of Science ®Google Scholar
• Durbin P. W., White D. L., Jeung N., Weitl F. L., Uhlir L. C., Jones E. C., Breunger F. W., Raymond K. N. Chelation of238Pu(IV)in vivo by 3,4,3-LICAM(C): effects of ligand methylation and pH. Health Phys. 1989; 56: 839
   PubMed Web of Science ®Google Scholar
• Mays C. W., Lloyd R. D., Jones C. W., Bruenger F. W., Taylor G. N., Durbin P. W., White D., Raymond K. N. Decorporation of Pu and Am from beagles with delayed daily injections of 3,4,3-LICAM(C) or ZnDTPA. Health Phys. 1986; 50: 530
   PubMed Web of Science ®Google Scholar
• Lloyd R. D., Bruenger F. W., Mays C. W., Atherton D. R., Jones C. W., Taylor G. N., Stevens W., Durbin P. W., Jeung N., Jones E. S., Kappel M. J., Raymond K. N., Weitl F. L. Removal of Pu and Am from beagles and mice by 3,4,3-LI-CAM(C) or 3,4,3-LICAM(S). Rad. Res. 1984; 99: 106
   PubMed Web of Science ®Google Scholar
• Durbin P. W., Jeung N., Rodgers S. J., Turowski P. N., Weitl F. L., White D. L., Raymond K. N. Removal of238Pu(IV) from mice by polycatecholate.-hydroxamate, or - hydroxypyridinonate ligands. Rad. Protection Dosimetry 1989; 26: 351
   Web of Science ®Google Scholar
• Markley J. F. Removal of polymeric plutonium from mice by combined therapy with the calcium chelate and pentaethyl ester of DTPA. Int. J. Rad. Biol. 1963; 7: 405
   Web of Science ®Google Scholar
• Bulman R. A., Griffin R. J. Investigations into techniques for removing intracellular plutonium. III. Plutonium decorporation with a partially lipophilic chelating agent. Naturwissenschaften 1981; 67: 483
   Google Scholar
• Blank M. L., Cress E. A., Byrd B. L., Washburn L. C., Snyder F. Liposomal encapsulated ZnDTPA for removing intracellular169Yb. Health Phys. 1980; 39: 913
   PubMed Web of Science ®Google Scholar
• Bulman R. A. Some aspects of the bioinorganic chemistry of the actinides. Coord. Chem. Rev. 1980; 31: 221
   Web of Science ®Google Scholar
• Piscator M. The nephropathy of chronic cadmium poisoning. Cadmium, E. C. Foulkes. Springer-Verlag, Berlin 1986; 179
   Google Scholar
• Shigematsu I., Kikuchi T., Nogawa K., Nomiyama K., Tohyama C. Critical Review on Critical Concentration of Cadmium in the Kidney. ILZRO Crit. Rev. Ser., International Lead Zinc Research Organization, Research Triangle Park, NC 1990; 93
   Google Scholar
• Roels H. A., Lauwerys R. R., Buchet J. P., Bernard A. M., Vos A., Overstyn M. Health significance of cadmium induced renal dysfunction: a five year follow up. Br. J. Ind. Med. 1989; 46: 755
   PubMedGoogle Scholar
• Nogawa K., Honda R., Kido T., Tsuritani I., Yamada Y., Ishizaki M., Yamaya H. A dose-response analysis of cadmium in the general environment with special reference to total cadmium intake limit. Environ. Res. 1989; 48: 7
   PubMed Web of Science ®Google Scholar
• Waalkes M. P., Watkins J. B., Klaassen C. D. Minimal role of metallothionein in decreased chelator efficacy for cadmium. Toxicol. Appl. Pharmacol 1983; 68: 392
   PubMed Web of Science ®Google Scholar
• Goyer R. A. Mechanisms of lead and cadmium nephrotoxicity. Toxicol. Lett. 1989; 46: 153
   PubMed Web of Science ®Google Scholar
• Shaikh Z. A., Lucis O. J. Biological differences in cadmium and zinc turnover. Arch. Environ. Health 1972; 24: 410
   PubMed Web of Science ®Google Scholar
• Von Burg R., Smith J. C. Biliary mobilization of cadmium by 2,3-dimercaptopropanol and some related compounds. J. Toxicol. Environ. Health 1980; 6: 75
   PubMed Web of Science ®Google Scholar
• Cherian M. G. Chelation of cadmium with BAL and DTPA in rats. Nature 1980; 287: 871
   PubMed Web of Science ®Google Scholar
• Cherian M. G. Biliary excretion of cadmium in rat. III. Effects of chelating agents and change in intracellular thiol content on biliary transport and tissue distribution of cadmium. J. Toxicol. Environ. Health 1980; 6: 379
   PubMed Web of Science ®Google Scholar
• Cherian M. G. Biliary excretion of cadmium in rat. IV. Mobilization of cadmium from metallothionein by 2,3-dimercaptopropanol. J. Toxicol. Environ. Health 1980; 6: 394
   Google Scholar
• Cherian M. G., Onosaka S., Carson G. K., Dean P. A. W. Biliary excretion of cadmium in rat. V. Effects of structurally related mercaptans on chelation of cadmium from metallothionein. J. Toxicol. Environ. Health 1982; 9: 389
   PubMed Web of Science ®Google Scholar
• Cherian M. G., Rodgers K. Chelation of cadmium from metallothioneinin vivo and its excretion in rats repeatedly injected with cadmium chloride. J. Pharmacol. Exp. Ther. 1982; 222: 699
   PubMed Web of Science ®Google Scholar
• Rau W., Planas-Bohne F. Enhancement of the kidney Cd burden by -SH containing chelating agents. Biol. Trace Element Res. 1989; 21: 227
   PubMed Web of Science ®Google Scholar
• Nordberg G. Chelating agents and cadmium toxicity. Environ. Health Perspect 1984; 54: 213
   PubMed Web of Science ®Google Scholar
• Andersen O. Oral cadmium exposure in mice: toxicokinetics and efficiency of chelating agents. Crit. Rev. Toxicol. 1989; 20: 83
   PubMed Web of Science ®Google Scholar
• Gale G. R., Smith A. B., Walker E. M., Jr. Diethyldithio-carbamate in treatment of acute cadmium poisoning. Ann. Clin. Lab. Sci. 1981; 11: 476
   PubMed Web of Science ®Google Scholar
• Jones S. G., Jones M. M., Basinger M. A., Burka L. T., Shinobu L. A. Polarity and antidotal efficacy of dithiocarbamates in acute cadmium intoxication. Res. Commun. Chem. Pathol. Pharmacol. 1983; 40: 155
   PubMedGoogle Scholar
• Jones S. G., Jones M. M. Structure-activity relationships among dithiocarbamate antidotes for acute cadmium chloride intoxication. Environ. Health Perspect. 1984; 54: 285
   PubMed Web of Science ®Google Scholar
• Gale G. R., Atkins L. M., Walker E. M., Jr., Smith A. B., Jones M. M. Mechanism of diethyldithiocarbamate, dihydroxyethyldithiocarbamate and dicarboxyrnethyldithiocarbamate action on distribution and excretion of cadmium. Ann. Clin. Lab. Sci. 1983; 13: 474
   PubMed Web of Science ®Google Scholar
• Shinobu L. A., Jones S. G., Jones M. M. SodiumN-methyl-d-glucamine dithiocarbamate and cadmium intoxication. Acta Pharmacol. Toxicol. 1984; 54: 189
   PubMedGoogle Scholar
• Kojima S., Kaminaka K., Kiyozumi M., Honda T. Comparative effects of three chelating agents on distribution and excretion of cadmium in rats. Toxicol. Appl. Pharmacol. 1986; 83: 516
   PubMed Web of Science ®Google Scholar
• Kojima S., Kiyozumi M., Honda T., Senba Y., Kaminaka K., Ohnishi M. Studies on poisonous metals. XVIII. Effects of several dithiocarbamates on tissue distribution and excretion of cadmium in rats. Chem. Pharm. Bull. 1987; 35: 3838
   PubMed Web of Science ®Google Scholar
• Jones S. G., Singh P. K., Jones M. M. Use of the Topliss scheme for the design of more effective chelating agents for cadmium decorporation. Chem. Res. Toxicol. 1988; 1: 234
   PubMed Web of Science ®Google Scholar
• Singh P. K., Jones S. G., Gale G. R., Jones M. M., Smith A. B., Atkins L. M. Selective removal of cadmium from aged hepatic and renal deposits: N-substituted talooctamine dithiocarbamates as cadmium mobilizing agents. Chem.-Biol. Interact. 1990; 74: 79
   PubMed Web of Science ®Google Scholar
• Jones M. M., Singh P. K., Jones S. G. Optimization for the mobilization of aged renal and hepatic deposits of cadmium: sodiumN-benzyl-4–0-(β-d-galactopyranosyl)-d-glucamineN-carbodithioate. Chem. Res. Toxicol. 1990; 3: 248
   PubMed Web of Science ®Google Scholar
• Singh P. K., Jones M. M., Jones S. G., Gale G. R., Atkins L. M., Smith A. B., Bulman R. A. Effect of chelating agent structure on the mobilization of cadmium from intracellular deposits. J. Toxicol. Environ. Health. 1989; 28: 501
   PubMed Web of Science ®Google Scholar
• Hansch C., Leo A. Substituent Constants for Correlation Analysis in Chemistry and Biology. John Wiley & Sons, New York 1979; 49
   Google Scholar
• Singh P. K., Gale G. R., Jones S. G., Jones M. M. Mobilization of agedin vivo cadmium deposits by dimethyl dimercapto-succinate. Toxicol. Lett. 1988; 41: 239
   PubMed Web of Science ®Google Scholar
• Jones M. M., Singh P. K., Gale G. R., Atkins L. M., Smith A. B. Esters of meso-dimercaptosuccinic acid as cadmiummobilizing agents. Toxicol. Appl. Pharmacol. 1988; 95: 507
   PubMed Web of Science ®Google Scholar
• Singh P. K., Jones M. M., Gale G. R., Atkins L. M., Smith A. B. The mobilization of intracellular cadmium by butyl and amyl esters of meso-2,3-dimercaptosuccinic acid. Toxicol. Appl. Pharmacol. 1989; 97: 572
   PubMed Web of Science ®Google Scholar
• Jones M. M., Cherian M. G. The search for chelate antagonists for chronic cadmium intoxication. Toxicology 1990; 62: 1
   PubMed Web of Science ®Google Scholar
• Rubin M., Gignac S., Bessman S. P., Belknap E. L. Enhancement of lead excretion in humans by disodium calcium ethylenediaminetetraacetate. Science 1953; 117: 659
   PubMed Web of Science ®Google Scholar
• Chisolm J. J., Jr., Harrison H. E. The treatment of lead encephalopathy in children. Pediatrics 1957; 19: 2
   PubMed Web of Science ®Google Scholar
• Hammond P. B. The effects of chelating agents on the tissue distribution and excretion of lead. Toxicol. Appl. Pharmacol. 1971; 18: 296
   PubMed Web of Science ®Google Scholar
• Catsch A. Der Einfluss von Chelatbildnern auf das Verhalten von Blei im Organismus. Arzneimttelforschung 1962; 12: 924
   PubMed Web of Science ®Google Scholar
• Hofmann U., Segewitz G. Influence of chelation therapy on acute lead intoxication in rats. Arch. Toxicol 1975; 34: 213
   PubMed Web of Science ®Google Scholar
• Friedheim E., Corvi C., Walker C. H. Meso-dimercaptosuccinic acid, a chelating agent for the treatment of mercury and lead poisoning. J. Pharm. Pharmacol. 1976; 28: 711
   PubMed Web of Science ®Google Scholar
• Bankowska J., Hine C. Retention of lead in the rat. Arch. Environ. Contam. Toxicol. 1985; 14: 621
   PubMed Web of Science ®Google Scholar
• Xu Z.-F., Jones M. M. Comparative mobilization of lead by chelating agents. Toxicology 1988; 53: 277
   PubMed Web of Science ®Google Scholar
• Llobet J. M., Domingo J. L., Paternain J. L., Corbella J. Treatment of lead intoxication. A quantitative comparison of a number of chelating agents. Arch. Environ. Contam. Toxicol. 1990; 19: 185
   PubMed Web of Science ®Google Scholar
• Needleman H. L., Schell A., Bellinger D., Leviton A., Allred E. N. The long-term effects of exposure to low doses of lead in childhood. N. Engl. J. Med. 1990; 322: 83
   PubMed Web of Science ®Google Scholar
• Needleman H. L., Gatsonis C. A. Low-level lead exposure and the IQ of children: a meta-analysis of modern studies. JAMA 1990; 263: 673
   PubMed Web of Science ®Google Scholar
• Ehle A. L., McKee D. C. Neuropsychological effect of lead in occupationally exposed workers: a critical review. Crit. Rev. Toxicol. 1989; 20: 237
   Web of Science ®Google Scholar
• Cory-Slechta D. A., Weiss B., Cox C. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy. J. Pharmacol. Exp. Ther. 1987; 243: 804
   PubMed Web of Science ®Google Scholar
• Jugo S., Maljkovic T., Kostial K. The effect of chelating agents on lead excretion in rats in relation to age. Environ. Res. 1975; 10: 271
   PubMed Web of Science ®Google Scholar
• Sorenson E. M. B., Moretti E. S., Lindenbaum A. Chelation therapy and tissue distribution and excretion of lead in mice. Arch. Environ. Contam. Toxicol. 1980; 9: 619
   PubMed Web of Science ®Google Scholar
• Brownie C. F., Aronson A. L. Comparative effects of Caethylenediaminetetraacetic acid (EDTA), ZnEDTA and ZnCaEDTA in mobilizing lead. Toxicol. Appl. Pharmacol. 1984; 75: 167
   PubMed Web of Science ®Google Scholar
• Chisolm J. J., Jr., Thomas D. J. Use of 2,3-dimercaptopropane-1-sulfonate in treatment of lead poisoning in children. J. Pharmacol. Exp. Ther. 1985; 235: 665
   PubMed Web of Science ®Google Scholar
• Graziano J. H., LoIacono N. J., Meyer P. Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. J. Pediatr. 1988; 113: 1
   PubMed Web of Science ®Google Scholar
• Fournier L., Thomas G., Garmier R., Buisine A., Houze P., Pradier F., Dally S. 2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med. Toxicol. 1988; 3: 499
   Google Scholar
• Aposhian H. V. DMSA and DMPS — water soluble antidotes for heavy metal poisoning. Annu. Rev. Pharmacol. Toxicol. 1983; 23: 193
   PubMed Web of Science ®Google Scholar
• Aposhian H. V. meso-2,3-Dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu. Rev. Pharmacol. Toxicol. 1990; 30: 279
   PubMed Web of Science ®Google Scholar
• Haust H. L., Innwood M., Spence J. D., Poon H. C., Peter F. Intramuscular administration of iron during long-term chelation therapy with 2,3-dimercaptosuccinic acid in a man with severe lead poisoning. Clin. Biochem. 1989; 22: 189
   PubMed Web of Science ®Google Scholar
• Selander S., Cramer K., Hallberg L. Studies in lead poisoning. Br. J. Ind. Med. 1966; 23: 282
   PubMedGoogle Scholar
• Shannon M. W., Graef J., Lovejoy F. H., Jr. Efficacy and toxicity of d-penicillamine in low level lead poisoning. J. Pediatr. 1984; 105: 523
   PubMedGoogle Scholar
• Shannon M., Grace A., Graef J. W. Use of penicillamine in children with small lead burdens. N. Engl. J. Med. 1989; 321: 379
   Web of Science ®Google Scholar
• Jugo S., Maljkovic T., Kostial K. Influence of chelating agents on the gastrointestinal absorption of lead. Toxicol. Appl. Pharmacol. 1975; 34: 259
   PubMed Web of Science ®Google Scholar
• Aono H., Araki S. The effects of CaEDTA injection on lead, copper and ALAD in erythrocyte, plasma and urine in lead-exposed workers: a 24-h observation. Int. Arch. Occup. Environ. Health 1984; 55: 13
   PubMed Web of Science ®Google Scholar
• Abu-Dari K., Hahn F. E., Raymond K. N. Lead sequestering agents. 1. Synthesis, physical properties and structures of lead thiohydroxamato complexes. J. Am. Chem. Soc. 1990; 112: 1519
   Web of Science ®Google Scholar
• Graziano J. H., Cuccia D., Friedheim E. The pharmacology of 2.3-dimercaptosuccinic acid and its potential use in arsenic poisoning. J. Pharmacol. Exp. Ther. 1978; 207: 1051
   PubMed Web of Science ®Google Scholar
• Tadlock C. H., Aposhian H. V. Protection of mice against the lethal effects of sodium arsenite by 2,3-dimercapto-1-propane-sulfonic acid and dimercaptosuccinic acid. Biochem. Biophys. Res. Commun. 1980; 94: 501
   PubMed Web of Science ®Google Scholar
• Aposhian H. V., Tadlock C. H., Moon T. E. Protection of mice against the lethal effects of sodium arsenite — a quantitative comparison of a number of chelating agents. Toxicol. Appl. Pharmacol. 1981; 61: 385
   PubMed Web of Science ®Google Scholar
• Stine E. R., Hsu C.-A., Hoover T. D., Aposhian H. V., Carter D. E. N-(2,3-Dimercaptopropyl)phthalamidic acid: protectionin vivo andin vitro, against arsenic intoxication. Toxicol. Appl. Pharmacol. 1984; 75: 329
   PubMed Web of Science ®Google Scholar
• Adams E., Jeter D., Cordes A. W., Kolis J. W. Chemistry of organometalloid complexes with potential antidotes: structure of an organoarsenic dithiolate ring. Inorg. Chem. 1990; 29: 1500
   Web of Science ®Google Scholar
• Basinger M. A., Forti R. L., Burka L. T., Jones M. M., Mitchell W. M., Johnson J. E., Gibbs S. J. Phenolic chelating agents as antidotes for acute uranyl acetate intoxication in mice. J Toxicol. Environ. Health. 1983; 11: 237
   Web of Science ®Google Scholar
• Chen W.-Z., Xie Y.-Y. Studies on uranium mobilization drugs: synthesis of two new types of phosphonic acid chelating agents. Acta Pharm. Sin. 1984; 19: 865
   Google Scholar
• Tao Z.-Q., Xu X.-H., Yan X.-M., Chen Z.-J., Zhang J.-S., Liang Y.-K., Xie Y.-Y. Detoxication and mobilization of uranium by catecholammic acid. Acta Pharmacol. Sin. 1987; 8: 284
   Web of Science ®Google Scholar
• Xu M.-Z., Xie Y.-Y. Studies on uranium mobilization agents. II. Synthesis of polyaminopolycarboxylic acid amides with catechol moieties. Acta Pharm. Sin. 1986; 21: 148
   Google Scholar
• Chen W.-Z., Xie Y.-Y. Studies on uranium mobilizing agents, III. synthesis of 2,3-dihydroxy-5-carboalkyloxybenzylaminocarboxylic acid amides chelating agents. Acta Pharm. Sin. 1987; 22: 62
   Google Scholar
• Hsieh Y.-Y., Chen W.-Z., Xu M.-Z., Tao Z.-Q., Liang Y.-Y., Xu X.-H., Yan X.-M., Zhang J.-S. New chelating agents for detoxication of metal poisoning. Plzen. Lek. Sb. Suppl. 1988; 56: 59
   Google Scholar
• Tao Z.-Q., Xu X.-H., Yan X.-M., Chen Z.-J., Zhang J.-S., Liang Y.-Y., Xie Y.-Y. Pharmacological studies on catecholamic acid, an efficient chelating agent for metal mobilization. Plzen. Lek, Sb. Suppl. 1988; 56: 95
   Google Scholar
• Ortega A., Domingo J. L., Gomez M., Corbetla J. Treatment of experimental acute uranium poisoning by chelating agents. Pharmacol. Toxicol. 1989; 64: 247
   PubMedGoogle Scholar
• Domingo J. L., Ortega A., Llobet J. M., Corbella J. Effectiveness of chelation therapy with time after acute uranium intoxication. Fundam. Appl. Toxicol. 1990; 14: 88
   PubMedGoogle Scholar
• Athar M., Misra M., Srivastava R. C. Evaluation of chelating drugs on the toxicity, excretion and distribution of nickel in poisoned rats. Fundam. Appl. Toxicol. 1987; 9: 26
   PubMedGoogle Scholar
• Misra M., Athar M., Hasan S. K., Srinivastava R. C. Alleviation of nickel-induced biochemical alterations by chelating agents. Fundam. Appl. Toxicol 1988; 11: 285
   PubMedGoogle Scholar
• Aposhian H. V., Dart R. C., Aposhian M. M., Dawson B. V. Tissue decorporation of polonium-210 in rats by DMPA. Res. Commun. Chem. Pathol. Pharmacol 1987; 58: 157
   PubMedGoogle Scholar
• Wilhelm M., Jäger D. E., Ohnesorge F. K. Aluminum toxicokinetics. Pharmacol. Toxicol 1990; 66: 4
   PubMedGoogle Scholar
• Martin R. B. The chemistry of aluminum as related to biology and medicine. Clin. Chem. 1986; 32: 1797
   PubMed Web of Science ®Google Scholar
• Martin R. B. Bioinorganic chemistry of aluminum. Metal Ions Biol. Systems 1988; 24: 1
   Google Scholar
• Cannata J. L., Domingo J. L. Aluminum toxicity in mammals: a minireview. Vet. Hum. Toxicol 1989; 31: 577
   PubMedGoogle Scholar
• Kaehny W. D., Alfrey A. C., Holman R. E., Shorr W. J. Aluminum transfer during hemodialysis. Kidney Int. 1977; 12: 361
   PubMed Web of Science ®Google Scholar
• McKinney T. D., Basinger M. A., Dawson E., Jones M. M. Serum aluminum levels in dialysis dementia. Nephron 1982; 32: 53
   PubMed Web of Science ®Google Scholar
• MacDonald T. L., Humphreys W. G., Martin R. B. Promotion of tubulin assembly by aluminumin vitro. Science 1987; 236: 183
   PubMed Web of Science ®Google Scholar
• Brown D. J., Ham K. N., Dawborn J. K., Xipell J. M. Treatment of dialysis osteomalacia with desferrioxamine. Lancet 1982; 2(8294)343
   PubMed Web of Science ®Google Scholar
• Melograna J. M., Yokel R. A. Effect of the chelator desferrioxamine on aluminum elimination in rabbits. Res. Commun. Chem. Pathol Pharmacol 1983; 40: 497
   PubMedGoogle Scholar
• Giordana R., Ioppolo A., Ciaralli L., Rubbiani M., Vernillo I., Costantini S. Aluminum removal after chronic intoxication in rats. Res. Commun. Chem. Pathol. Pharmacol. 1989; 63: 119
   PubMedGoogle Scholar
• Domingo J. L., Gomez M., Llobet J. M., Corbella J. Citric, malic and succinic acids as possible alternatives to deferoxamine in aluminum toxicity. J. Toxicol. Clin. Toxicol. 1988; 26: 67
   PubMed Web of Science ®Google Scholar
• Magos L. Mercury. Handbook on the Toxicity of Inorganic Compounds, H. G. Seiler, H. Sigel, A. Sigel. Marcel Dekker, New York 1988; 419
   Google Scholar
• Sunderman F. W. Perils of mercury. Ann. Clin. Lab. Sci. 1988; 18: 89
   PubMed Web of Science ®Google Scholar
• Aposhian H. V., Aposhian M. M. N-Acetyl-d,l-penicillamine, a new oral protective agent against the lethal effects of mercuric chloride. J. Pharmacol. Exp. Ther. 1959; 126: 131
   PubMed Web of Science ®Google Scholar
• Magos L. The effects of dimercaptosuccinic acid on the excretion and distribution of mercury in rats and mice treated with mercuric chloride and methylmercuric chloride. Br. J. Pharmacol 1976; 56: 478
   Web of Science ®Google Scholar
• Aaseth J., Alexander J., Raknerud N. Treatment of mercuric chloride poisoning with dimercaptosuccinic acid and diuretics: preliminary studies. J. Toxicol. Clin. Toxicol. 1982; 19: 173
   PubMed Web of Science ®Google Scholar
• Lund M. E., Clarkson T. W., Berlin M. Treatment of acute methylmercury ingestion by hemodialysis withN-acetyl cysteine (mucomyst) infusion and 2,3-dimercaptopropane sulfonate. J. Toxicol. Clin. Toxicol. 1984; 22: 31
   PubMed Web of Science ®Google Scholar
• Cherian M. G., Miles E. F., Clarkson T. W., Cox C. Estimation of mercury burdens in rats by chelation with dimercaptopropane sulfonate. J. Pharmacol Exp. Ther. 1988; 245: 479
   PubMed Web of Science ®Google Scholar
• Campbell J. R., Clarkson T. W., Omar M. D. The therapeutic use of 2,3-dimercaptopropane-1-sulfonate in two cases of inorganic mercury poisoning. JAMA 1986; 256: 3127
   PubMed Web of Science ®Google Scholar
• Twardowska-Saucha K. Evaluation of the chelating action of methicillin in prolonged experimental metallic mercury poisoning. Br. J. Ind. Med. 1986; 43: 611
   PubMedGoogle Scholar
• Safirstein R., Winston J., Goldstein M., Moel D., Dikman S., Guttenplan J. Cisplatin-induced nephrotoxicity. Am. J. Kid. Dis. 1986; 8: 356
   PubMed Web of Science ®Google Scholar
• Daugaard G., Abildgaard U. Cisplatin nephrotoxicity. Cancer Chemother. Pharmacol. 1989; 25: 1
   PubMed Web of Science ®Google Scholar
• Borch R. F., Pleasants M. E. Inhibition of cis-platinum nephrotoxicity by sodium diethyldithiocarbamate rescue in a rat model. Proc. Natl. Acad. Sci. U.S.A. 1979; 76: 6611
   PubMed Web of Science ®Google Scholar
• Howell S. B., Taetle R. Effect of sodium thiosulfate on cisdichlorodiammineplatinum(II) toxicity and antitumor activity. Cancer Res. 1980; 64: 611
   Google Scholar
• Zunino F., Tofanetti O., Besati A., Cavalletti E., Savi G. Protective effect of reduced glutathione against cis-dichlorodiammineplatinum(II)-induced nephrotoxicity and lethal toxicity. Tumori 1983; 69: 105
   PubMed Web of Science ®Google Scholar
• Basinger M. A., Jones M. M., Holscher M. A. l-Methionine antagonism of cis-platinum nephrotoxicity. Toxicol. Appl. Pharmacol. 1990; 103: 1
   PubMed Web of Science ®Google Scholar
• Aamdal S., Fodstand Ø., Pihl A. Some procedures to reduce cis-platinum toxicity reduce antitumor activity. Cancer Treat. Rev. 1987; 14: 389
   PubMed Web of Science ®Google Scholar
• Wagner T., Kreft B., Bohlmann G., Schweider G. Effects of fosfomycin, mesna and sodium thiosulfate on the toxicity and antitumor activity of cispaltin. J. Cancer Res. Clin. Oncol. 1988; 114: 497
   PubMed Web of Science ®Google Scholar
• Gandara D. R., Perez E. A., Phillips W. A., Lawrence H. J., De Gregorio M. Evaluation of cisplatin dose intensity: current status and future prospects. Anticancer Res. 1989; 9: 1121
   PubMed Web of Science ®Google Scholar
• Howell S. B., Pfeifle C. E., Wung W. E., Olshen R. A. Intraperitoneal cis-diamminedichloroplatinum(II) with systemic thiosulfate protection. Cancer Res. 1983; 43: 1426
   PubMed Web of Science ®Google Scholar
• Kuroiwa T., Aoki K., Taniguchi S.-I., Hasuda K., Baba T. Efficacy of two-route chemotherapy using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, in combination with angiotensin II in a rat limb tumor model. Cancer Res. 1987; 47: 3618
   PubMed Web of Science ®Google Scholar
• Funk F., Lenders J.-P., Critchon R. R., Schneider W. Reductive mobilisation of ferritin iron. Eur. J. Biochem. 1985; 152: 167
   PubMedGoogle Scholar
• Topham R., Goger M., Pearce K., Schultz P. The mobilization of ferritin iron by liver cytosol. Biochem. J. 1989; 261: 137
   PubMed Web of Science ®Google Scholar
• Harris W. R. Kinetics of the removal of ferric ion from transferrin by aminoalkylphosphonic acids. J. Inorg. Biochem. 1984; 21: 263
   PubMed Web of Science ®Google Scholar
• Harris W. R., Rezvani A. B., Bali P. K. Removal of iron from transferrin by pyrophosphate and tripodal phosphonate ligands. Inorg. Chem. 1987; 26: 2711
   Web of Science ®Google Scholar
• Goyer R. A., Cherian M. G. Ascorbic acid and EDTA treatment of lead toxicity in rats. Life Sci. 1979; 24: 433
   PubMed Web of Science ®Google Scholar
• Dhawan M., Kachru D. N., Tandon S. K. Influence of thiamine and ascorbic acid supplementation on the antidotal efficacy of thiol chelators in experimental lead intoxication. Arch. Toxicol. 1988; 62: 301
   PubMed Web of Science ®Google Scholar
• Dalley J. W., Gupta P. K., Hung C. T. A physiological pharmacological model describing the disposition of lead in the absence and presence of l-ascorbic acid in rats. Toxicol. Lett. 1990; 50: 337
   PubMed Web of Science ®Google Scholar
• Tandon S. K., Flora S. J. S., Singh S. Chelation in metal intoxication. XXIV. Influence of various components of vitamin B complex on the therapeutic efficacy of disodium calcium versenate in lead intoxication. Pharmacol. Toxicol. 1987; 60: 62
   PubMedGoogle Scholar
• Bratton G. R., Zmudzki J., Bell M. C., Warnock L. G. Thiamin (vitamin B1) effects on lead intoxication and deposition of lead in tissues: therapeutic potential. Toxicol. Appl. Pharmacol 1981; 59: 164
   PubMed Web of Science ®Google Scholar
• Jones M. M., Singh P. K., Jones S. G., Holscher M. A. Dithiocarbamates of improved efficacy for the mobilization of aged cadmium from renal and hepatic deposits, Submitted
   Google Scholar
• Bulman R. A. Interaction of chelating agents with bone. Trace Metals and Fluoride in Bones and Teeth, N. B. Priert, Van de Vyver. CRC Press, Boca Raton, FL 1990, chap. 12.
   Google Scholar
• Shanzer A., Libman J., Lifson S., Felder C. E. Origin of the Fe3+-binding and conformational properties of enterobactin. J. Am. Chem. Soc. 1986; 108: 7609
   PubMed Web of Science ®Google Scholar
• Bourari A., Fathallah M., Blaive B., Gallo R. Design and molecular mechanics calculations of new iron chelates. J. Chem. Soc. Perkin Trans. 1990; 2: 1211
   Google Scholar
• Jones M., Cherian M. G. The search for chelate antagonists for chronic cadmium intoxication. Toxicology 1990; 62: 1
   PubMed Web of Science ®Google Scholar
• Hruby K., Donner A. 2,3-Dimercapto-1-propanesulphonate in heavy metal poisoning. Med. Toxicol. 1987; 2: 317
   Google Scholar